



Final Appraisal Recommendation

Advice No: 2021 – December 2021

Clostridium botulinum neurotoxin type A (Xeomin®) 50, 100, 200 units/vial powder for solution for injection

**Licence extension for paediatric use submission by
Merz Pharma UK Ltd**

Recommendation of AWMSG

Clostridium botulinum neurotoxin type A (Xeomin®) is recommended as an option for use within NHS Wales for the symptomatic treatment in children and adolescents aged 2 to 17 years and weighing ≥ 12 kg of chronic sialorrhoea due to neurological/neurodevelopmental disorders.

This recommendation applies only in circumstances where the approved Patient Access Scheme (PAS) is utilised or where the list/contract price is equivalent or lower than the PAS price.

Additional note(s):

- See NICE guidance for botulinum neurotoxin Type A (Xeomin®) for treating chronic sialorrhoea (TA605, originally published October 2019).

In reaching the above recommendation AWMSG has taken account of the appraisal documentation prepared by the AWMSG Secretariat (reference number 3986), which includes the All Wales Therapeutics and Toxicology Centre (AWTTC) assessment, clinical expert opinion (where available), the views of patients/patient carers (where available) and the lay member perspective.

This recommendation has been ratified by Welsh Government and will be considered for review every three years.

Statement of use: No part of this recommendation may be reproduced without the whole recommendation being quoted in full and cited as:

All Wales Medicines Strategy Group Final Appraisal Recommendation – 2021:
Clostridium botulinum neurotoxin type A (Xeomin®) 50, 100, 200 units/vial powder for solution for injection